Financial Data and Key Metrics Changes - Total revenue for Q2 2025 reached $727 million, reflecting a 9% year-over-year increase, driven by a 12% growth in the cloud business [5][20] - Earnings per share for Q2 were $3.1, a 14% increase compared to the previous year [27] - Cloud revenue contributed $541 million, representing 74% of total revenue, with a net revenue retention (NRR) of 111% [20][21] Business Line Data and Key Metrics Changes - Customer Engagement revenue, which accounted for 82% of total revenue, increased by 8% year-over-year to $597 million [26] - Financial Crime and Compliance revenue, representing 18% of total revenue, grew by 19% year-over-year to $130 million [26] - AI and self-service annual recurring revenue (ARR) grew by 42% year-over-year to $238 million, now constituting 11% of cloud revenue [20][21] Market Data and Key Metrics Changes - International revenue increased by 13% year-over-year, with EMEA revenue up 111% on a constant currency basis [24][25] - APAC revenue grew by 17% year-over-year, also on a constant currency basis [25] - The company secured significant contracts, including a landmark agreement with the Department of Work and Pensions valued over $100 million [15] Company Strategy and Development Direction - The company is focused on leading the AI transformation in customer experience, emphasizing the integration of AI capabilities into its CXone mPOWER platform [5][10] - Strategic partnerships with industry leaders like ServiceNow, AWS, and Salesforce are being leveraged to enhance market presence and product offerings [12][18] - The acquisition of Cognigy is expected to further strengthen AI capabilities and customer engagement solutions [17][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a 12% growth target for cloud revenue for the full year, despite some short-term challenges with LiveVox [34][61] - The company anticipates continued strong performance in AI and self-service solutions, which are expected to drive future growth [5][21] - Management highlighted the importance of maintaining operational rigor while investing in growth opportunities [18][27] Other Important Information - The company repurchased shares totaling $31 million in Q2, maintaining a robust balance sheet with total cash and investments of $1.632 billion [27][28] - The planned acquisition of Cognigy is expected to close in 2025, pending regulatory approval [29][30] Q&A Session Summary Question: How is the company thinking about the level of investment and operating margins? - Management indicated that investments are focused on international expansion and cloud growth, expecting a 50 basis point increase in operating margins year-over-year [32][33] Question: What gives confidence in the 12% growth target for cloud revenue? - Management noted solid performance in Q1 and Q2, with expectations to maintain the 12% growth in Q3, despite some challenges with LiveVox [34][61] Question: Can you elaborate on the renewed partnership with RingCentral? - The partnership renewal was seen as beneficial for both companies, leveraging strengths in CCaaS and UCaaS to provide integrated solutions for customers [47][51] Question: What is causing the underperformance in LiveVox? - Management cited higher-than-expected churn in LiveVox's customer base, leading to dilution in organic growth [52][53] Question: Are there any signs of softness in the fourth quarter? - Management stated they do not see signs of softness and expect continued strong performance across a diversified customer base [95][96] Question: What is the outlook for large deals in the pipeline? - Management confirmed a strong pipeline of large deals, indicating ongoing demand for integrated AI capabilities in customer experience solutions [64][66]

Financial Data and Key Metrics Changes - The combined net revenue for Q2 2025 was approximately $3 million, representing a 35% increase compared to Q1 2025 and a 10% increase compared to Q2 2024 [6][29] - Loss from operations increased by $800,000 from $7.2 million in Q2 2024 to $8 million in Q2 2025 [30] - Net loss attributable to common shareholders increased by approximately $900,000 from $9.5 million in Q2 2024 to $10.4 million in Q2 2025 [30] Business Line Data and Key Metrics Changes - Mytesi prescription volume increased by approximately 6.5% in 2025 compared to 2024, with Q2 2025 volume equal to Q2 2024 [29] - The company is focusing on business development partnerships for licensing rights to its products, aiming to generate non-dilutive funding [7] Market Data and Key Metrics Changes - The company is conducting trials for Crofelimer in pediatric patients with MVID and short bowel syndrome, with initial results showing significant benefits [10][11] - The prevalence of MVID is estimated to be just a couple of hundred patients globally, indicating a niche market opportunity [12] Company Strategy and Development Direction - The company aims to seek business development partnerships to enhance funding opportunities during a period of reduced investor support for emerging pharma companies [7] - The strategy includes expanding the indication of Crofelimer for cancer therapy-related diarrhea, targeting metastatic breast cancer patients [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the convergence of key clinical and regulatory catalysts in 2025, which are expected to enhance value for stakeholders [6][31] - The company is preparing to submit a protocol to the FDA for a pivotal treatment trial for Crofelimer in metastatic breast cancer patients [23] Other Important Information - The company is also pursuing regulatory approval for Canalevia, a product for chemotherapy-induced diarrhea in dogs, with plans to expand its indication [25][26] - The company is in discussions with potential partners for both human and animal health products [26] Q&A Session Summary - No specific questions or answers were recorded in the provided content, indicating that the session may have concluded without a formal Q&A segment [34]

Financial Data and Key Metrics Changes - The company reported an adjusted EBITDA of INR 27.2 billion, representing a 43% year-over-year growth [6] - Profit after tax for the quarter was INR 5.1 billion, exceeding the profit for the entire fiscal year 2025 [6] - The leverage at the operating asset level was around 5.7 times EBITDA, which is below the six times threshold set by the company [14] Business Line Data and Key Metrics Changes - The manufacturing business produced 900 megawatts of modules and 400 megawatts of cells in the quarter, contributing INR 5.3 billion to adjusted EBITDA [7][10] - The operational capacity of the manufacturing business is 6.4 gigawatts for modules and 2.5 gigawatts for cells [7] - The company revised its FY 2026 adjusted EBITDA guidance from the manufacturing business upwards to INR 8 billion to 10 billion [8] Market Data and Key Metrics Changes - The company commissioned around 2.25 gigawatts of renewable energy capacity, marking a 23% growth in its portfolio after adjusting for asset sales [5] - Year-to-date, the company has commissioned more than 700 megawatts, with over 650 megawatts of solar capacity and about 50 megawatts of wind [9] Company Strategy and Development Direction - The company aims to be a global leader in clean energy and is focused on improving margins and capital discipline to create shareholder value [4][5] - The company plans to complete the construction of 1.6 to 2.4 gigawatts of capacity in fiscal 2026 and is selective in bidding for future growth [6][23] - The company is committed to its ESG initiatives, having reduced Scope one and Scope two emissions by 18.2% from the FY 2022 baseline [8][17] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are factors beyond their control, they remain focused on executing their strategy and improving operational efficiency [5] - The bidding environment is steady, with the government aiming for 500 gigawatts by 2030, but competition has become more irrational, affecting win ratios [32][33] - Management expressed optimism about signing PPAs from the current pipeline in the fiscal year [9] Other Important Information - The company received a final, revised non-binding offer at USD 8 on July 3, with ongoing discussions expected to update shareholders by September 30, 2025 [14] - The company secured a significant investment from British International Investments for over USD 100 million for a 10% stake in the solar manufacturing business [10] Q&A Session Summary Question: Inquiry about manufacturing business production volumes - The company sold almost 700 megawatts of modules to third parties in Q1 FY 2026, with a balance used for internal consumption [28] Question: Expectations for the back half of the year regarding sales - The company anticipates continued contribution from third-party sales throughout the year, with visibility on guidance provided [31] Question: Update on the bidding environment - The bidding environment remains steady, with the government auctioning 50 to 70 gigawatts annually, but competition has become more aggressive [32][33] Question: Key issues facing the renewable sector - Management noted occasional delays in transmission infrastructure and land acquisition as key issues, but overall capacity addition is proceeding at a reasonable pace [43][44] Question: Participation in recent ammonia tenders - The company did not participate in the ammonia tenders due to concerns over contract structures and the need for selective bidding [51][52]

Financial Data and Key Metrics Changes - The company experienced a 50% increase in revenues from selling goods compared to the same period last year [3] - Revenues from selling goods were $15.4 million for Q2 2025, an increase of $2.1 million or 16% compared to $13.3 million for Q2 2024 [12] - Net income for Q2 2025 was approximately $164,000 or $0 per share, compared to a net loss of approximately $2.2 million or $0.03 per share for the same period in 2024 [16] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by sales of Elfabrio to Chiesi, with an increase of $8 million in sales to Chiesi, partially offset by a decrease of $4.7 million in sales to Brazil and $1.2 million in sales to Pfizer [12] - Research and development expenses increased by $3 million or 100% to approximately $6 million in Q2 2025, primarily due to preparations for the planned Phase II clinical trial of PRX-115 [14] Market Data and Key Metrics Changes - The global market for Fabry disease is approximately $2.3 billion in 2025 and is forecasted to reach approximately $3.2 billion by 2030 [4] - The company anticipates El Fabryo royalties exceeding $100 million by 2030 based on a projected 15% to 20% market share of the estimated $3.2 billion Fabry total market [6] Company Strategy and Development Direction - The company is focused on building its product development pipeline, particularly in early-stage development assets and therapeutic areas related to renal rare diseases [8] - The company plans to initiate a Phase II study for PRX-115 in 2025 and enroll the first patient in Q4 2025 [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic plan and the foundation being built for future growth, emphasizing the excitement around the Phase II program for PRX-115 [18] - The management noted that Chiesi has been performing better than expected in the marketplace, with significant growth in patient acquisition [28] Other Important Information - The company had $33.4 million in cash and cash equivalents and short-term bank deposits as of June 30, 2025 [16] - Eyal Rubens, the Chief Financial Officer, is stepping down after six years, and Gilad Mambloc will succeed him [9][10] Q&A Session Summary Question: Comments on Chiesi's planned study called Pagasso - Management confirmed it is part of Chiesi's phase four program to enhance the merits and strengths of the program [22][23] Question: Details on the Phase II trial for PRX-115 - The company plans to operate between 20 to 30 sites for the trial, primarily in the U.S. [24][25] Question: Market share held by Chiesi in Fabry disease - Management stated they do not disclose specific market share numbers but assured that Chiesi is performing well and growing its market share [27][28] Question: Utilization of Gilad's experience in business development - Management clarified that while Gilad has significant experience, the company is currently not planning any mergers or acquisitions and is focusing on growing its pipeline [30][32]

Financial Data and Key Metrics Changes - The company ended the quarter with cash and cash equivalents of $11 million, down from $23.3 million as of December 31, 2024, indicating a significant decrease in liquidity [11] - Research and development expenses for the quarter were approximately $2.4 million, a decrease from $7.3 million in the same period last year, reflecting a conclusion of patient enrollment and follow-up for a significant clinical study [12] - General and administrative expenses decreased to $3.6 million from $6.4 million year-over-year, primarily due to reduced pre-commercialization efforts [12] - The net loss for the quarter was $5.4 million, or $3.39 per share, compared to a net loss of $900,000, or $0.77 per share, in the same period last year [13] Business Line Data and Key Metrics Changes - The lead asset, iapofacine I-131, is positioned for accelerated approval with the FDA, reflecting a strategic shift in regulatory approach [5][6] - The company is advancing its next-generation radiopharmaceutical pipeline, with CLR125 and CLR225 expected to enter clinical trials in late 2025 or early 2026 [9][10] Market Data and Key Metrics Changes - The company anticipates a response from the EMA regarding conditional marketing authorization for iapofacine I-131 late in Q3 or early Q4 2025, indicating ongoing engagement with European regulatory bodies [7] - The market potential for iapofacine I-131 is considered compelling, supported by robust clinical data and a well-understood safety profile [9] Company Strategy and Development Direction - The company is focused on delivering innovative, life-extending therapies for cancer patients, with a clear regulatory strategy for accelerated approval in the US and conditional marketing authorization in Europe [21][22] - Active discussions with potential partners are underway to secure non-dilutive capital and expertise, which will support the company's strategic initiatives [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the new regulatory strategy for iapofacine I-131, highlighting the importance of the twelve-month follow-up data and the shift to earlier lines of therapy [29] - The company remains committed to advancing its clinical programs and regulatory milestones, with a focus on expanding its impact into solid tumors [21][22] Other Important Information - The company raised nearly $10 million in recent financings to support clinical programs and regulatory milestones [10] - The anticipated costs for the confirmatory study related to iapofacine I-131 are estimated to be between $40 million and $45 million [40] Q&A Session Summary Question: Status of the WM program and EU approval path - Management is finalizing the protocol for an accelerated approval confirmatory study and expects to submit the NDA later this year or early next year, pending sufficient capital [27][29] Question: Concerns regarding preclinical biodistribution data - The biodistribution data indicates approximately 25% to 30% of the infused drug reaches the tumor, with off-target activity generally below 5% in other tissues, primarily the liver [32] Question: Timing and costs associated with NDA submission - The estimated cost for the confirmatory study is approximately $40 million to $45 million, with $20 million to $25 million needed for full enrollment and necessary data [40][41]

Financial Data and Key Metrics Changes - The company reported net product sales of $9.7 million for Q2 2025, representing a 33% increase year-over-year and a 10% increase sequentially, marking the highest quarterly net product sales in the company's history [14][20][24] - Total cash operating expenses for the quarter were approximately $11 million, an increase of roughly $2 million compared to Q1 2025, driven by ongoing investments in marketing and additional headcount [22][24] Business Line Data and Key Metrics Changes - The company achieved three consecutive quarters of growth in Pedmark sales, with the addition of 14 new accounts in Q2, including large community oncology groups [15][20] - The company is focused on establishing Pedmark as the standard of care for cisplatin-induced ototoxicity (CIO) prevention, with positive feedback from existing accounts strengthening confidence in clinical value [10][11] Market Data and Key Metrics Changes - The AYA (adolescent and young adult) market is identified as significantly larger than the pediatric market, with approximately 20,000 patients treated with cisplatin in that demographic [31] - The company is seeing strong momentum in both large community practices and academic centers, indicating a growing recognition of the need for Pedmark [9][10] Company Strategy and Development Direction - The company aims to stabilize the business and build a foundation for sustainable growth, focusing on increasing awareness and adoption of Pedmark [6][8] - The strategic imperatives include enhancing patient support services, cementing Pedmark as the standard of care, and expanding educational efforts beyond oncologists to other healthcare professionals [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the scalability of the business model and the growing demand for Pedmark, anticipating significant quarterly growth in 2025 [20][21] - The company is optimistic about the partnership with Norgene in the EU, expecting to provide updates on milestones and royalties in future quarters [21][40] Other Important Information - The company has made significant progress with payers and providers to ensure smoother coverage and fewer barriers for treatment sites [12] - The company plans to ring the closing bell at NASDAQ on September 5, 2025, symbolizing its mission to help patients [14] Q&A Session Summary Question: Can you share the active prescribers number, particularly within AYA? - The company does not disclose cumulative active prescriber numbers but acknowledges the importance of protecting relationships with accounts [28][30] Question: What is the mix of new and repeat customers? - Initially, the company focused on new customers, but there is now a shift towards a higher percentage of repeat customers as the business grows [44][46] Question: Can you elaborate on the Japanese market opportunity? - Japan represents about a third of the size of the U.S. and Europe in terms of CIO usage, with ongoing discussions about regulatory approaches and potential partnerships [49][50] Question: What are the expectations for operating expenses in the second half of the year? - The company expects cash operating expenses to decrease in the second half of the year, consistent with previous years [55][56] Question: How proactive has the FDA been regarding compliance with guidance on Pedmark? - The FDA has been supportive of the use of Pedmark and continues to emphasize its status as the only FDA-approved product for preventing cisplatin-induced hearing loss [70][71] Question: What is the timeline for the Norgene partnership in the EU? - The Norgene partnership has launched in the UK and is expected to expand to other EU markets early next year, with significant enthusiasm for the product [74][75]

Marpai (MRAI) Q2 2025 Earnings Call August 14, 2025 08:30 AM ET Speaker0Good morning, and welcome to the Marpay Second Quarter twenty twenty five Earnings Webcast. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Steve Johnson, Chief Financial Officer.Please go ahead.Speaker1Thank you, and welcome this morning to our Marpay Second Quarter Earnings ...

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was approximately $13.2 million, down from approximately $17 million in the same period last year, representing a decline of about 22% [7] - Year-to-date revenue was approximately $27.8 million compared to approximately $34.5 million for the same period last year, indicating a decrease of about 19% [7] - Gross profits from the healthcare segment decreased to approximately 20% in 2025 from 35% in 2024, primarily due to decreased prescription volume and changes in 340B revenue [10] - Gross profits from the e-commerce segment decreased to approximately 26% in 2025 from 32% in 2024, attributed to new airtime costs and temporary rate reductions for some customers [10] - Cash position at the end of Q2 was approximately $16.6 million [11] Business Line Data and Key Metrics Changes - Healthcare operations revenue declined due to decreased pharmacy prescription volume and changes in provider relationships [8] - E-commerce operations experienced an increase in revenue driven by growth in recurring airtime revenue and hardware sales [9] Market Data and Key Metrics Changes - E-commerce sales in China showed steady progress, limited by inventory import capabilities [4] - The tariff situation in the U.S. remains volatile, affecting operations in Florida [4] Company Strategy and Development Direction - The company is focused on refining healthcare operations, including personnel changes and improving operational efficiency [13] - New hires include pharmacy operations managers to enhance long-term growth and strategic planning [14] - The company is pursuing specialty pharmacy accreditation to access new revenue sources [15] Management Comments on Operating Environment and Future Outlook - Management acknowledges challenges in healthcare operations but sees potential for growth through cost reductions and operational efficiencies [5] - The company is committed to transparency and proactive steps to address challenges and invest for long-term success [16] Other Important Information - The company has not yet repurchased any shares under its repurchase program but plans to be active in the coming quarter [17] - The company is closely monitoring compliance with NASDAQ requirements and is prepared to utilize the grace period if necessary [18] Q&A Session Summary Question: What is the status of the buyback? - The company has not repurchased any shares yet but expects to be active in the coming quarter while being prudent with cash deployment [17] Question: What is the plan to regain compliance with NASDAQ? - The company is monitoring the situation and believes that executing strategic developments will be central to regaining compliance [18] Question: Should the company consider closing its business in China? - The company acknowledges tariff challenges but sees potential in the OpCo products and plans to launch animal health products in China [19]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was €26,100,000, representing a 4.9% year-over-year increase, with a 21% growth excluding The Netherlands [6][20] - Gross profit increased by 10.8% year-over-year to €13,700,000, with a gross profit margin of 52.7%, up 280 basis points [6][22] - Adjusted EBITDA for Q2 2025 was €3,500,000, a decrease of 4.3% from the same period in 2024, resulting in an adjusted EBITDA margin of 13.3% [7][22] Business Line Data and Key Metrics Changes - Proprietary content revenue grew by 270% year-over-year, contributing 14.8% of total revenue in Q2 2025, up from 10.8% a year ago [10][24] - The PAM and Turnkey segments generated CAD3.8 million, accounting for 14.6% of total revenue, down from CAD4.9 million or 19.9% in the same period last year [23] - Aggregated content made up 49.4% of revenue, slightly down from 49.6% the previous year [23] Market Data and Key Metrics Changes - In The Netherlands, the company experienced a 17% decline, outperforming the industry which saw a 25% decline [10][22] - The U.S. market showed significant growth, with proprietary content revenue increasing by 270% year-over-year [10][15] - Brazil's iGaming market is projected to grow from US$3.9 billion in 2025 to US$6.1 billion by 2030, with the company expecting Brazil to account for up to 10% of its revenue in 2025 [17] Company Strategy and Development Direction - The company is focusing on margin improvement and cash flow performance over aggressive revenue expansion due to increasing gaming taxes in key markets [7][27] - A strategic shift is underway to reduce reliance on The Netherlands, with projections indicating a decrease in revenue contribution from 49% in 2022 to 32% in 2025 [31] - The company aims to become an AI-first business by 2027, embedding AI into product development and operations to enhance player engagement and operational efficiency [18][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver sustainable profitable growth despite lower-than-expected top-line growth [28] - The company anticipates continued advancements in predictive analytics and the adoption of generative AI for scalable content creation [33] - Management highlighted the importance of diversifying revenue sources and leveraging proprietary content for profitability [31][43] Other Important Information - The company has made key hires to strengthen its leadership in content development and AI innovation [17][18] - A planned realization of cost synergies is expected to provide €2,000,000 in annualized cash savings [8] Q&A Session Summary Question: Revenue contribution from Hard Rock and Caesars - Management indicated a path to reach the previously mentioned 15% revenue contribution from proprietary content, with optimism about performance in the second half of the year [38][39] Question: Future growth opportunities - Management elaborated that highly accretive growth opportunities lie in proprietary content, with a focus on increasing production capabilities [42][43] Question: FX impact on guidance - There was a slight impact from the euro weakening against the US dollar, but it was not significant [41]

Financial Data and Key Metrics Changes - Product revenue increased 105% to $1,700,000 in Q3 2025 compared to $800,000 in Q3 2024, with a year-to-date increase of 100% to $6,400,000 from $3,200,000 [4][13] - Product gross margins improved to 53.9% in Q3 2025 from 34.1% in Q3 2024, with gross profit rising to $900,000 from $300,000 [4][14] - Net loss improved to $1,500,000 or a loss of $0.03 per share in Q3 2025, compared to a net loss of $2,800,000 or a loss of $0.10 per share in Q3 2024 [17] - Cash and cash equivalents increased to $8,000,000 as of June 30, 2025, from $1,500,000 as of September 30, 2024 [18] Business Line Data and Key Metrics Changes - Licensing revenue of $3,000,000 was generated in the first nine months of fiscal 2025, compared to no licensing revenue in the same period of fiscal 2024, derived from an expanded agreement with Zimmer Biomet [13][14] - Total operating expenses decreased 9% to $2,800,000 in Q3 2025 compared to $3,100,000 in Q3 2024, with R&D expenses stable at $1,200,000 [15][16] Market Data and Key Metrics Changes - The company is pursuing market opportunities in pain management, including trigeminal neuralgia and lower back pain treatments, with potential revenue generation expected in late 2025 [6][7] - The spinal cord stimulation market is estimated to generate over $3,000,000,000 in annual revenue, representing a significant opportunity for the company [8] Company Strategy and Development Direction - The company aims to expand its product portfolio in pain management and other therapeutic applications, leveraging its thin film ablation technology [6][7] - Plans to initiate a post-market registry to collect outcomes data for patients treated with the 1RF ablation system, highlighting positive patient outcomes [5][6] Management's Comments on Operating Environment and Future Outlook - Management reiterated expectations of being funded through at least fiscal year 2026 based on contractual minimum orders and potential cash flow breakeven if key milestones are achieved [5][18] - The company is confident in its fiscal year 2025 guidance, expecting product revenue to be in the range of $8,000,000 to $10,000,000, representing a significant increase over fiscal year 2024 [12] Other Important Information - The company has received its first international patent for its spinal cord stimulation electrode and is in the process of securing ISO certification for international commercialization [10][11] - New hires in the management team are expected to contribute positively and bring cost savings [11] Q&A Session Summary Question: Can you provide an update on the drug delivery platform and its testing status? - The devices are currently ordered for initial bench testing, followed by animal testing, with human trials planned if animal testing is successful [21][22] Question: What is the market potential for trigeminal ablation and the physician specialties involved? - Approximately 150,000 people in the US suffer from trigeminal neuralgia, with potential procedures being similar to brain ablations, targeting the same physician specialties [25][26] Question: Can you discuss the design and target levels for spinal cord stimulation? - The therapy targets lower back pain, likely from L3, L4 to S1, with multiple components expected in the system [27][28] Question: Any outlook for 2026? - The company is not providing a forecast for 2026 at this time, but remains confident in its current range due to minimum purchase requirements from Zimmer [30]